Bedrijfsoverzicht
Aurora Cannabis Inc. is a specialized manufacturer within the healthcare sector that engages in the production, distribution, and sale of pharmaceutical-grade cannabis and cannabis-derivative products across Canada and international markets. Operating through distinct segments focused on Canadian Cannabis and Plant Propagation, the company serves the drug manufacturers - specialty & generic industry, which requires adherence to strict regulatory standards for medicinal products. The enterprise maintains a market capitalization of $194.51M and reported annual revenue of $373.12M, though specific employee headcount data is not disclosed in the provided records. These valuation and revenue figures indicate that the company operates as a mid-sized entity within the broader cannabis landscape, possessing a substantial asset base and revenue stream relative to the high-growth but often fragmented nature of the industry. The scale of its operations, evidenced by a multi-million dollar market cap and significant annual revenue, suggests an established presence capable of competing in both domestic and international markets while managing complex supply chains for cannabis derivatives.
Financiële gezondheid
The company reported a trailing twelve-month revenue of $373.12M, which contrasts sharply with a net income of $-83,512,000 and an EBITDA of $-32,735,000, revealing a cost structure where operating expenses significantly erode pre-tax profits before interest and taxes. Despite the negative net income, the firm generated positive free cash flow of $11.86M, which indicates a degree of financial flexibility allowing the business to potentially fund operations or reduce debt without immediate external financing. The gross margin stands at 36.0%, suggesting that production costs are controlled relative to the selling price of cannabis products, yet the operating margin of 2.3% and profit margin of -22.5% demonstrate that overhead and other operational costs are substantial enough to negate gross profitability at the bottom line. The balance sheet shows a cash position of $108.45M against total debt of $101.00M, resulting in a debt-to-equity ratio of 17.79, which characterizes the company as highly leveraged with a net cash position that mitigates immediate liquidity risk. Short-term liquidity is robust as evidenced by a current ratio of 3.06, indicating that current assets are more than three times the value of current liabilities. However, the return on equity of -15.5% and return on assets of -4.4% reveal that management is currently unable to generate positive returns on the capital invested in the business, highlighting the challenges of scaling profitability in this sector.
Waarderingsbeoordeling
The valuation metrics present a complex picture with a trailing P/E ratio of N/A due to losses, while the forward P/E is listed at -31.18, implying that the market expects earnings to remain negative or requires significant turnaround to achieve positive valuation multiples. The price-to-book ratio is 0.50, indicating that the market values the company at half its book value, which suggests a significant discount often seen in distressed or turnaround situations rather than a premium for growth. Alternative valuation measures such as the price-to-sales ratio of 0.52 and an EV/EBITDA of -6.68 further reflect the earnings challenges, as negative EV/EBITDA typically signals that the company is not yet generating sufficient operating cash flow relative to its enterprise value. The stock has traded between a 52-week high of $6.67 and a 52-week low of $3.07, placing the current trading environment within a wide volatility range that reflects investor uncertainty regarding future profitability. With a beta of 1.32, the stock exhibits higher price volatility relative to the broader market, moving more aggressively than the market index and amplifying both potential gains and losses for risk-tolerant participants.
Growth & Income
Revenue growth for the year over year stands at 6.8%, whereas earnings growth is -94.7%, indicating that earnings are shrinking much faster than revenue, which implies that top-line expansion is not yet translating into bottom-line improvement due to high fixed costs or margin compression. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that any generated free cash flow is retained within the organization to fund operations, repay debt, or invest in growth initiatives rather than being distributed to shareholders. This reinvestment strategy is typical for companies in the development phase that prioritize operational scaling and market share acquisition over income generation for investors. Overall, the growth and income profile of Aurora Cannabis Inc. is characterized by top-line expansion coupled with significant earnings contraction and a reliance on cash reserves to sustain operations while pursuing profitability.